**Seeking Medical Treatment Abroad: The Best CAR-T Therapy is in China! The First Russian Multiple Myeloma Patient Successfully Achieves Complete Tumor Clearance and CR!**

patient story

Over the five years following his diagnosis of high-risk multiple myeloma, Mr. F endured relentless pain. Despite undergoing various chemotherapy regimens and two transplants, he could never completely escape the nightmare of unpredictable tumor recurrence and progression. Fortunately, by the end of 2023, his condition temporarily stabilized. Accompanied by top hematology experts from Russia, Mr. F traveled to China to receive CAR-T therapy, achieving optimal results with complete tumor eradication and CR (complete remission).

Achieved CR! In February 2024, Mr. F and his family successfully returned to Russia to resume their happy lives.

(Note: To protect patient privacy, pseudonyms are used in the text, and the medical details and treatment process have been slightly modified.)

Mr. F, 63, is the vice principal of a technical college in St. Petersburg, Russia. He has a successful career and a happy family with his wife, one son, and two daughters. In the months leading up to Christmas 2017, Mr. F experienced worsening back pain, with severe pain in the lumbar region. Accompanied by his family, he went to the hospital for a thorough examination. The final diagnosis was multiple myeloma, with osteolytic lesions in more than three areas. The doctor informed Mr. F that, based on the comprehensive assessment of various test results, his myeloma was classified as high-risk (IgG-type, DS-Stage IIIA, ISS-Stage II), making it difficult to treat, prone to relapse, and with a poor prognosis. This devastating news struck suddenly, plunging the entire family into shock and panic. In an interview, Mr. F said, “In Chinese culture, Confucius said, ‘When Heaven is about to place a great responsibility on a man, it always first frustrates his spirit,’ viewing it as a life test. In Western culture, it is seen as God’s punishment, a trial one must endure, with the outcome entirely dependent on how one faces these challenges. I must choose to fight!”

After two days of shock and panic, Mr. F decided to pull himself together and seek the best treatment to fight the tumor. Mr. F and his family consulted many doctors and clinics in Spain, Munich, and Heidelberg. Upon learning that CAR-T therapy had remarkable curative effects on hematologic malignancies, they felt a glimmer of hope, which was soon extinguished. At that time, very few countries offered CAR-T therapy, mostly in developed nations, and the exorbitant cost of nearly a million dollars made it unaffordable even for the well-off Mr. F. To control the disease as quickly as possible, Mr. F underwent traditional CVD therapy in Russia at the beginning of 2018, followed by his first autologous bone marrow transplant, achieving partial remission (PR). Unfortunately, just ten months later, his multiple myeloma relapsed. After switching to a second-line chemotherapy regimen, he underwent a second autologous bone marrow transplant. Despite receiving the most aggressive treatment and enduring life-threatening side effects, tumor lesions persisted in his body, like a ticking time bomb that could explode at any moment. Although maintenance therapy temporarily stabilized the disease, Mr. F and his family remained vigilant. They knew that high-risk myeloma was likely to relapse and progress again in the short term. If the disease worsened once more, they would face a desperate situation with no available treatments.

To completely rid himself of cancer and escape the nightmare of constant relapse and deterioration, five years later, Mr. F and his family once again sought the possibility of a cure through CAR-T therapy worldwide. They conducted extensive research on the CAR-T therapies already on the market and consulted numerous hospitals and experts in Europe, including in India and Israel. To his surprise, despite five years passing, there had been no significant progress in these countries. Almost every expert mentioned that Chinese hospitals had made tremendous advancements in the CAR-T field, surpassing even those in Europe and the United States. Especially for multiple myeloma, on June 30, 2023, China introduced the world’s first fully human BCMA CAR-T therapy, Iquilence. Mr. F and his attending physician immediately contacted Shanghai Jiahui International Hospital in China for an initial remote consultation. Jiahui Hospital, an internationally aligned oncology center with a professional multidisciplinary MDT team, conducted a preliminary evaluation. They concluded that the Iquilence (BCMA CAR-T) treatment plan would be most beneficial and developed a comprehensive plan, addressing all questions and concerns of Mr. F and the Russian experts, ultimately reaching a consensus on the treatment plan.

Professor Li Hua, Director of Oncology at Jiahui International Cancer Center, and his team of Russian hematology experts discussed Mr. F’s treatment plan. Although Mr. F was somewhat aware of China’s medical advancements, he couldn’t imagine that China’s healthcare had surpassed that of the developed Western countries. Therefore, in November 2023, Mr. F’s attending physician, a renowned Russian hematology expert, accompanied him to China to evaluate the feasibility of Chinese CAR-T therapy on-site. Their first stop upon arriving in China was to meet with Jiahui Hospital’s international multidisciplinary treatment team and tour the medical environment that adheres to international nursing standards.

Professor Li Hua, Director of Jiahui International Cancer Center, and his team provided a detailed introduction to the CAR-T treatment plan. Compared to traditional treatments, CAR-T has unique advantages. Firstly, it is a highly personalized treatment that adjusts the patient’s immune system through genetic engineering, providing a more precise response to cancer treatment. Secondly, CAR-T shows significantly higher efficacy in complex cases, which traditional treatments cannot achieve. Iquilence has an overall response rate of nearly 99% and a complete response rate of up to 82.4%. More importantly, fully human CAR-T not only maintains the patient’s quality of life but also provides more durable treatment effects. Additionally, a one-time infusion treatment achieves rapid and effective results, reducing the pain and burden during the treatment process and bringing hope for a cure.+

The second stop for Mr. F and the Russian experts was a visit to the production facility of the world’s first fully human BCMA CAR-T therapy, Iquilence. Mr. F and the Russian experts were impressed to learn that this exceptional therapy was not only entirely developed in-house, but the lentiviral vector was also independently developed. The facility boasts a complete end-to-end development platform and a self-built manufacturing base.

Finally, Mr. F overcame all his concerns and was convinced that China’s fully human BCMA CAR-T solution was world-leading. He decided to undergo treatment in China.

All Tumors Cleared for the First Time, Advanced Myeloma Achieves CR!

In December 2023, just before another Christmas five years after his diagnosis, Mr. F and his family arrived in China, full of hope for a cure, to officially begin his CAR-T journey. At Shanghai Jiahui International Hospital, Mr. F underwent thorough examinations, and after meeting all the requirements, he successfully underwent apheresis, the process of collecting T cells. These cells were then transported back to the factory within 24 hours to create a precisely targeted anti-cancer weapon tailored for Mr. F.

On January 20, 2024, he received lymphodepleting chemotherapy with fludarabine and cyclophosphamide.

On January 25, 2024, the CAR-T cells, carrying the hopes of Mr. F’s entire family, were transported to him by the pharmacy team using professional cold chain logistics. After multiple inspections, unpacking, and reactivation, a small bag of milky white liquid was infused back into Mr. F. The doctors explained that this liquid contained hundreds of billions of “special forces” T cells, which, once in the body, would begin an intense sweep to eradicate the myeloma cells completely.

The infusion process went smoothly. What deeply moved Mr. F and his family was that whenever he felt anxious, the medical team would hold his hand, giving him confidence and strength.

Although a mild cytokine release syndrome (CRS), which is common after CAR-T therapy, occurred post-infusion, the medical team at Jiahui Hospital was very experienced in handling this. With symptomatic treatment, the symptoms improved in about a week. On the 14th day after the infusion, the evaluation showed that the CAR-T cells had expanded effectively in Mr. F’s body, reaching 10^9.

Mr. F said that, unlike the two painful transplant experiences, despite knowing that CAR-T therapy has side effects, the medical team clearly informed him about the reactions he might have at different stages and assured him that the medical staff would address them immediately. As a result, he felt no concerns or fears.

Before the Chinese New Year in 2024, Mr. F was discharged and returned to Russia for further follow-up in his home country. Professor Li Hua said, “The treatment results met our expectations, with significant improvements in key indicators such as serum M protein, free light chains, and disease symptoms. All functional statuses have improved.”

In May 2024, the PET-CT results showed that Mr. F’s lesions had disappeared, and he finally achieved complete remission (CR). This means that after battling multiple myeloma for six years, he has finally won!

A Brighter Future: China Will Become the Best Treatment Destination for Advanced Myeloma Patients!

Now, Mr. F not only resumes his happy and fulfilling life, but he and his wife have also returned to their beloved careers. He currently serves as the General Manager of the UNESCO Mineral Resources Education Center.

Mr. F said, “When I came to China and saw the medical conditions and experienced the best care firsthand, I felt a deep sense of pride for China. It is regrettable that Russia is currently unable to achieve this level of care. However, I will bring my experiences here back to Russia and share them. China’s medical system is world-leading, and choosing to come to China was the right decision!”

In an interview, Mr. F’s wife said, “Although we are past retirement age, we both have very important careers. This CAR-T treatment in China has given us a very precious experience. We have more time to listen to each other’s thoughts, support each other, and get through difficult times together.”

Professor Li Hua, Director of the International Oncology Hospital and Director of the Department of Oncology, said in an interview:

“Clinical research on CAR-T therapy started relatively early in China. Especially since 2020, the number of CAR-T clinical trials in China has far surpassed that in the United States, giving us extensive experience from laboratory research to clinical application.

Moreover, CAR-T treatment in China is more cost-effective, providing patients with a more competitive option.

Most importantly, China has sufficient commercial-quality production capacity. Patients can receive treatment quickly without waiting, which is crucial for those with malignant hematologic diseases who need timely treatment.”

Professor Li Hua, Director of Oncology at Jiahui International Hospital,

The emergence of CAR-T cell therapy has brought new hope to cancer patients worldwide. China’s CAR-T therapy offers outstanding efficacy, good safety, low cost, and rapid preparation advantages. Several international hospitals have opened green channels for overseas patients, making China the best treatment destination for global late-stage multiple myeloma patients!

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago Myeloma

Chinese Medical Team: Long Survival and Significant Benefits with BCMA CAR-T Treatment for RRMM: A 5-Year Outlook

**Chinese Medical Team: Long Survival and Significant Benefits with BCMA CAR-T Treatment for RRMM: A 5-Year Outlook**

RRMM

Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising new treatments for relapsed/refractory multiple myeloma (RRMM), but reports on its long-term efficacy and safety are limited. As early as 2022, Professor Du Juan’s team from the Department of Hematology at Shanghai Changzheng Hospital published a Phase I/II study demonstrating that patients with poor physical status could also benefit from CAR-T therapy. Recently, the team updated their findings with a five-year long-term follow-up, focusing on factors affecting long-term clinical benefits. The results were published in *Clinical Cancer Research*. The following summary of the study’s content is provided by *Cancer Information* for readers’ benefit.

### Evidence for Long-Term Efficacy and Safety of BCMA CAR-T Cell Therapy

#### Patient Characteristics

The study included 49 RRMM patients who had all received at least three prior lines of therapy before undergoing BCMA CAR-T cell treatment. At enrollment, 20 patients (40.82%) had poor physical status (ECOG performance status of 3-4), 42.86% had high-risk cytogenetic features, and 63.27% had received four or more lines of treatment. At the time of infusion, 79.59% had progressive disease. Among the patients with poor physical status, 30% had extramedullary disease (EMD), 45% had high-risk cytogenetic features, 70% had received four or more lines of treatment, and 80% had progressive disease after their last line of treatment.

#### Efficacy Evaluation of BCMA CAR-T Cell Therapy HDS269B

After a median follow-up of 59.0 months, the study showed an overall response rate (ORR) of 77.55%. The ORR was similar across patients with different ECOG scores. The median progression-free survival (PFS) was 9.5 months, and the median overall survival (OS) was 20.0 months. The five-year PFS and OS rates were 21.3% and 31.4%, respectively. For patients with ECOG scores of 0-2, the median PFS was 11.0 months, compared to 4.0 months for those with scores of 3-4 (P=0.18). The median OS was 41.8 months for ECOG 0-2 patients and 10.5 months for ECOG 3-4 patients (P=0.015).

Patients who had previously undergone four or more lines of therapy had significantly shorter PFS and OS compared to those who had received fewer than four lines (PFS: P=0.012; OS: P=0.0049). Among the 11 patients with EMD at enrollment, the ORR was 64% for those with EMD and 82% for those without EMD. However, median PFS and OS were notably shorter in patients with EMD (PFS: 3.0 months vs. 10.5 months, P=0.06; OS: 5.0 months vs. 24.0 months, P=0.03).

#### MRD-Negative Status and CAR-T Cell Persistence Indicate Better Long-Term Survival

Minimal residual disease (MRD) negativity was significantly associated with longer PFS and OS. In this study, MRD data were available for 22 patients on day 28 post-infusion, with 14 patients (63.64%) achieving MRD negativity (10^-4). These patients experienced significantly longer PFS and OS compared to MRD-positive patients. Similar associations were observed with MRD status at 3 and 6 months post-infusion.

The expansion of CAR-T cells was also closely related to clinical outcomes. Patients who achieved partial response (PR) or better had higher CAR-T cell peak levels. Patients without disease progression five years post-infusion had significantly higher CAR-T cell expansion peaks than those with progression. Additionally, the duration of CAR-T cell persistence correlated with longer PFS and OS, with patients having CAR-T cells persisting for ≥6 months, ≥12 months, ≥24 months, and ≥36 months showing significantly better PFS and OS than those without detectable CAR-T cells.

#### Controlled Safety Profile of BCMA CAR-T Cell Therapy HDS269B

No new CAR-T cell-related toxicities were observed during long-term follow-up. All patients experienced at least one adverse event (AE), with the most common long-term (≥28 days post-infusion) grade ≥3 AEs being hematologic in nature. No second primary malignancies or delayed immune effector cell-associated neurotoxicity syndrome (ICANS) were observed.

This study also included survival analysis, classifying patients by PFS and OS. The results indicated that ECOG 0-2 status, fewer than four prior therapies, and CAR-T cell persistence for ≥6 months were independently associated with longer survival.

### The Potential of BCMA CAR-T Therapy and the Need for Future Optimization

Through a five-year long-term follow-up of 49 RRMM patients, this study systematically evaluated the efficacy and safety of BCMA CAR-T cell therapy HDS269B. The findings suggest that poor physical status is not a contraindication for CAR-T therapy, thus broadening the indications for this treatment. While the results are encouraging, the study has some limitations, including its open-label, single-arm design and small sample size, which, combined with the long follow-up period, could lead to some patient attrition. Furthermore, despite the lack of new severe toxicities, long-term safety requires continued observation.

Overall, this study underscores the importance of BCMA CAR-T cell therapy in the treatment of RRMM and provides a crucial basis for exploring and applying CAR-T immunotherapy in the frontline treatment of multiple myeloma.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +86137 1795 9070

Email: doctor.huang@globecancer.com

#CAR_Therapy #BCMACART #MultipleMyeloma #CancerResearch #LongTermSurvival #MedicalInnovation #Hematology #CancerTreatment #Immunotherapy #OncologyAdvances

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago CAR-T

#EBMT / #EHA Leading the Frontiers of Medicine: China’s Top Medical Expert Explains the Groundbreaking CAR-T Cell Therapy

#EBMT / #EHA Leading the Frontiers of Medicine: China’s Top Medical Expert Explains the Groundbreaking CAR-T Cell Therapy

Expert:**Huang He**

Chief Physician and Doctoral Supervisor.

Currently serves as the Director of the Hematology Institute at Zhejiang University, Director of the Zhejiang Provincial Engineering Research Center for Stem Cell and Cellular Immunotherapy, Chief Scientist for the “Hematology and Immunology Diseases” division at the Liangzhu Laboratory, and Director of the Bone Marrow Transplantation Center at the First Affiliated Hospital of Zhejiang University School of Medicine.

He is the Vice Chairman of the Asia Cell Therapy Organization and Deputy Leader of the Hematopoietic Stem Cell Application Group of the Hematology Branch of the Chinese Medical Association.

He has published over 300 papers (including over 200 as corresponding author) in journals such as The New England Journal of Medicine, Nature, Cell Metabolism, Lancet Haematology, Blood, and Leukemia.

He has received 17 provincial and ministerial-level awards and holds 23 authorized invention patents.

In the past five years, he has served as chairperson, invited speaker, and oral presenter at over 60 international conferences. As the conference chair, he organized the Asia-Pacific International Bone Marrow and Hematopoietic Stem Cell Transplantation Conference in Hangzhou in 2005 and 2014.

He is the chief editor of “CAR-T Cell Immunotherapy” and “Hematology” published by People’s Medical Publishing House.

He serves on the editorial boards and committees of multiple international journals and organizations.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in Chinafor preliminary evaluation!

WhatsApp:+8613717959070
Email: doctor.huang@globecancer.com

#MedicalInnovation #CAR_Therapy #Hematology #MedicalBreakthrough #ExpertTalks #CuttingEdgeMedicine #cart #EHA2024

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

7 months ago Myeloma

The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company

The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company

Mutiple myeloma

#Legend Biotech

How to advance #CARTcell therapy to frontline treatment is the goal every CAR-T company strives for. On April 5, 2024, local time, Chinese pharmaceutical company Legend Biotech (LEGN.NS) shared exciting news as the U.S. Food and Drug Administration (#FDA) officially approved #ciltacabtageneautoleucel for treating relapsed or refractory multiple myeloma patients. This significant decision brings new hope to patients who have undergone first-line treatment and developed resistance to standard therapies.

 

#Ciltacabtagene autoleucel

Ciltacabtagene autoleucel becomes the world’s first CAR-T product approved for second-line treatment! This milestone event paves the way for Legend Biotech to enter the global CAR-T market. What’s even more inspiring is that just the day before, the FDA approved BMS’s CAR-T therapy Abecma for third-line treatment of multiple myeloma. The approval of ciltacabtagene autoleucel signifies the strong competitiveness and innovation capabilities of Chinese pharmaceutical companies in the CAR-T field.

 

Marketing

As early as February 28, 2022, ciltacabtagene autoleucel was first approved for marketing in the United States for the treatment of relapsed or refractory multiple myeloma in adults. As a pioneer of Chinese original CAR-T cell therapy, the successful market launch of this drug has won new glory for China’s biopharmaceutical industry. Currently, ciltacabtagene autoleucel is marketed in the United States, European Union, and Japan, and is also undergoing regulatory review in China, expected to be marketed domestically soon.

 

Personalized Immunotherapy

The CEO of Legend Biotech stated that the expanded indication of ciltacabtagene autoleucel is expected to change the treatment landscape of multiple myeloma, providing physicians and patients with a personalized immunotherapy option for early treatment. Multiple myeloma is an incurable and progressive hematologic malignancy, thus urgently requiring innovative treatment options, for which ciltacabtagene autoleucel is designed.

HOPE

The successful approval of ciltacabtagene autoleucel not only brings hope to patients but also outlines a new chapter for the future development of CAR-T therapy. In this hopeful moment, let’s look forward to CAR-T technology bringing health and happiness to more patients in the future!

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: 137 1795 9070

#LegendBiotech #CARTcell #MultipleMyelomaTreatment #Innovation #Hope

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago CAR-T

🎉 #PNAS Breaking News: Revolutionary CAR-T Cell Therapy Successfully Treats Autoimmune Disease in China! 🎉

🎉 #PNAS Breaking News: Revolutionary CAR-T Cell Therapy Successfully Treats Autoimmune Disease in China! 🎉

PNAS

In a groundbreaking development, Chinese medical experts have achieved a milestone in the treatment of autoimmune diseases using CAR-T cell therapy.

🩺 A New Hope for Autoimmune Diseases

Autoimmune-mediated necrotizing myopathy (#IMNM) poses a significant challenge in clinical management due to its severe symptoms and limited efficacy of traditional pharmacological approaches. However, a ray of hope emerges with the application of Chimeric Antigen Receptor (CAR) T-cell therapy targeting B cell maturation antigen (#BCMA).

🔬 The Breakthrough Study

Published in the prestigious #journal PNAS, the study titled “Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy” by the medical team at Huazhong University of Science and Technology sheds light on a remarkable case. A patient with anti-signal recognition particle (SRP) IMNM exhibited significant improvement in clinical symptoms and sustained reduction in pathogenic autoantibodies after receiving BCMA-targeted CAR-T cell therapy for over 18 months.

🧬 Understanding the Mechanisms

Through longitudinal single-cell RNA sequencing and analysis of T cell receptors and B cell receptors, researchers elucidated the normalization of the immune microenvironment post-CAR-T cell infusion. The expansion of CD8+ CAR-T cells, coupled with dynamic phenotypic transitions in both CD4+ and CD8+ CAR-T cells, was observed, indicating a promising avenue for the treatment of autoimmune diseases.

🔍 Implications for the Future

This study not only highlights the efficacy of CAR-T cell therapy in refractory IMNM but also underscores the importance of understanding the molecular characteristics of CAR-T cells in autoimmune diseases. Further research is warranted to enhance the efficiency and durability of CAR-T cell therapy for autoimmune conditions.

🌟 Hope for Patients Worldwide

With this groundbreaking achievement, there is renewed hope for millions of individuals battling autoimmune diseases globally. Stay tuned for more updates as we continue to unlock the potential of innovative therapies in medical science!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

#CAR_TTherapy #AutoimmuneDisease #MedicalBreakthrough #Science #Innovation #PNAS #cart #cartcell #BCMA #IMNM #chineseresearch #medicalscience

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 months ago patient story

🍀Miraculous Journey Across Borders: Mr. Barankov’s Triumph with CAR-T Therapy in China 🍀

🍀Miraculous Journey Across Borders: Mr. Barankov’s Triumph with CAR-T Therapy in China 🍀

Hope of patients

🌱Meet Mr. Barankov

    a 68-year-old patient from Saint Petersburg, Russia, who was unexpectedly diagnosed with multiple myeloma in 2018. After four years of international consultations, he discovered that China has made significant advancements in CAR-T therapy compared to European medical institutions in Spain, Munich, Heidelberg, and others. 

 

🌿The treatment outcomes in China are leading globally.

    Following unsuccessful traditional chemotherapy and two autologous hematopoietic stem cell transplants, he had the opportunity for an online consultation with experts from Jiahui International Hospital in Shanghai. During the virtual consultation, Mr. Barankov was impressed by the expertise of the Chinese medical team and the therapeutic potential of the fully human CAR-T drug FUCASO (Eque-cel). Considering China’s leading position in CAR-T therapy, more competitive costs, and relatively shorter wait times, Mr. Barankov made a significant decision to travel to China for treatment.

 

☘️#MiracleJourney #CARTTherapy #CrossingBorders #CART #Hopeofpatients #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

9 months ago Myeloma

Chinese Medical Research！丨New Target CAR-T Cell Therapy in R/R MM Patients Sparks Hope and Shapes the Future

🌟Chinese Medical Research！🌟

丨New Target CAR-T Cell Therapy in R/R MM Patients Sparks Hope and Shapes the Future

GPRC5D, Multiple Myeloma

🌷”#JournalofClinicalOncology” 🌷

          brings hope for patients with relapsed/refractory #MultipleMyeloma (R/R MM) through a groundbreaking CAR-T cell therapy targeting a “new bull’s eye”.

 

🌻Led by Professor Xu Kailin’s team

          from Affiliated Hospital of Xuzhou Medical University, this study delved into the efficacy and safety of CAR-T cell therapy targeting GPRC5D in R/R MM patients.

 

🌼GPRC5D, 

          a member of the G-protein coupled receptor family, showed significantly higher expression on malignant and normal plasma cells in bone marrow compared to peripheral blood cells, laying the groundwork for it to be a prime target for CAR-T cell therapy.

 

🌺In this study involving 33 R/R MM patients, all received CAR-T cell therapy targeting GPRC5D, with remarkable results! The overall response rate hit 91%(ORR), including a strict complete response rate of 33%. Notably, patients previously treated with BCMA-targeted CAR-T therapy also saw partial or better responses.

 

🪷Despite these strides in efficacy, safety remains a key concern. The most common adverse events included hematologic toxicities like neutropenia, anemia, and thrombocytopenia, along with cytokine release syndrome and neurotoxicity.

          This study’s findings shine a beacon of hope for R/R MM patients. The GPRC5D-targeted CAR-T cell therapy displays promising clinical efficacy and manageable safety, offering a potential alternative for those progressing after BCMA therapy or developing resistance.

 

🥀This breakthrough not only expands treatment options for MM patients but also sets a new course for the future development of CAR-T cell therapy.

 

🌹To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp+8613717959070

doctor.huang@globecancer.com

 

#CARTCellTherapy #MultipleMyeloma #ClinicalResearch #HopeForTheFuture #MedicalBreakthroughs #newhope #BCMA #cart #gprc5d #cartcell #celltherapy

• 1
• 2
• 3